NEC versus NET G3—is there a grey zone? Case report of pancreatic NET G3 with rapid disease progression
Philipp Melhorn,
Markus Raderer,
Peter Mazal
et al.
Abstract:Summary
Introduction
Patients with well-differentiated neuroendocrine tumors of grade 3 (NET G3) exhibit a significantly better survival than patients with poorly differentiated neuroendocrine carcinomas (NEC). However, some cases of NET G3 with high Ki-67 index present with highly aggressive clinical behavior, prompting the question whether there are selected tumors representing a biological continuum between NET G3 and NEC.
Case presentation
… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.